
ARTV
Healthcare · Biotechnology · $198.2M market cap
$4.01+0.05 (+1.3%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -21.8% over 90 days · 30-day revisions 0 up, 2 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 9, 2026 | After the close | -0.54 | -0.56 | -3.7% |
| Aug 6, 2026 | After the close | -0.64 | -0.63 | +1.6% |
| May 8, 2026 | Before the open | -0.88 | -0.95 | -8.0% |
| Mar 30, 2026 | Time not confirmed | -0.80 | -0.84 | -5.0% |
| Nov 12, 2025 | Before the open | -0.80 | -0.88 | -10.0% |
| Aug 7, 2025 | Before the open | -0.77 | -0.87 | -13.0% |
| May 8, 2025 | Before the open | -0.62 | -0.83 | -33.9% |
| Mar 24, 2025 | Time not confirmed | -0.58 | -0.66 | -13.8% |
| Nov 12, 2024 | After the close | -0.63 | -0.87 | -38.1% |
| Aug 29, 2024 | After the close | -4.40 | -22.00 | -400.0% |
| May 29, 2024 | Time not confirmed | — | -1.49 | — |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid…